Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RG3421 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | po daily |
| RG3421 120mg | EXPERIMENTAL | 120mg po daily |
| RG3421 20mg | EXPERIMENTAL | 20mg po daily |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | po daily |
| RG3421 120mg | DRUG | 120mg po daily |
| RG3421 20mg | DRUG | 20mg po daily |
Inclusion Criteria: * adult patients, 18-70 years of age; * medically stable, moderate to severe chronic plaque psoriasis. Exclusion Criteria: * any skin condition which may interfere with evaluation of the effect of study medication on plaque lesions; * confounding or concomitant condition or tr...
RG3421 is an investigational small molecule being developed for the treatment of psoriasis, specifically moderate to severe chronic plaque psoriasis. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
RG3421 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with psoriasis.
RG3421 is in Phase 2 clinical development. A Phase 2 study has been completed, and the drug remains investigational. It has not received regulatory approval and is not yet available for commercial use.
RG3421 has one completed Phase 2 clinical trial, identified as NCT00504270. This study evaluated the drug in 66 patients with moderate to severe chronic plaque psoriasis in the United States. The trial was randomized, double-blind, and placebo-controlled.
No, RG3421 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for psoriasis. The completed Phase 2 trial was a randomized, double-blind, placebo-controlled study, but the drug has not yet received regulatory approval.